Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annika Pasanen

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Duodecim; Laaketieteellinen Aikakauskirja|December 15, 2017
Clinical significance of gene defects in B-cell lymphomasAnnika Pasanen, Leo Meriranta, Sirpa Leppä
The Journal of Biological Chemistry|May 20, 2008
Characterization of recombinant human prolyl 3-hydroxylase isoenzyme 2, an enzyme modifying the basement membrane collagen IVPäivi Tiainen, Annika Pasanen, Raija Sormunen, et al.
Cellular and Molecular Life Sciences : CMLS|April 12, 2011
Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia responseMinna Heikkilä, Annika Pasanen, Kari I Kivirikko, et al.
The International Journal of Biochemistry & Cell Biology|April 27, 2010
Hypoxia-inducible factor (HIF)-3alpha is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2Annika Pasanen, Minna Heikkilä, Kati Rautavuoma, et al.
Blood Advances|August 12, 2020
Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphomaLeo Meriranta, Annika Pasanen, Amjad Alkodsi, et al.
Leukemia|June 13, 2019
Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genesAmjad Alkodsi, Alejandra Cervera, Kaiyang Zhang, et al.
American Journal of Human Genetics|September 3, 2011
High myopia caused by a mutation in LEPREL1, encoding prolyl 3-hydroxylase 2Shikma Mordechai, Libe Gradstein, Annika Pasanen, et al.
Hemasphere|March 19, 2025
Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trialElin Forsgren, Rasmus R K Jørgensen, Hans Bentzen, et al.
Blood Advances|May 22, 2025
Circulating Tumor DNA Determinants of Response and Outcome in Relapsed/Refractory Mantle Cell LymphomaLeo Meriranta, Rasmus Rask Kragh Jørgensen, Annika Pasanen, et al.
Blood Advances|December 19, 2023
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trialMats Jerkeman, Arne Kolstad, Martin Hutchings, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Duodecim; Laaketieteellinen Aikakauskirja|December 15, 2017
Clinical significance of gene defects in B-cell lymphomasAnnika Pasanen, Leo Meriranta, Sirpa Leppä
The Journal of Biological Chemistry|May 20, 2008
Characterization of recombinant human prolyl 3-hydroxylase isoenzyme 2, an enzyme modifying the basement membrane collagen IVPäivi Tiainen, Annika Pasanen, Raija Sormunen, et al.
Cellular and Molecular Life Sciences : CMLS|April 12, 2011
Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia responseMinna Heikkilä, Annika Pasanen, Kari I Kivirikko, et al.
The International Journal of Biochemistry & Cell Biology|April 27, 2010
Hypoxia-inducible factor (HIF)-3alpha is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2Annika Pasanen, Minna Heikkilä, Kati Rautavuoma, et al.
Blood Advances|August 12, 2020
Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphomaLeo Meriranta, Annika Pasanen, Amjad Alkodsi, et al.
Leukemia|June 13, 2019
Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genesAmjad Alkodsi, Alejandra Cervera, Kaiyang Zhang, et al.
American Journal of Human Genetics|September 3, 2011
High myopia caused by a mutation in LEPREL1, encoding prolyl 3-hydroxylase 2Shikma Mordechai, Libe Gradstein, Annika Pasanen, et al.
Hemasphere|March 19, 2025
Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trialElin Forsgren, Rasmus R K Jørgensen, Hans Bentzen, et al.
Blood Advances|May 22, 2025
Circulating Tumor DNA Determinants of Response and Outcome in Relapsed/Refractory Mantle Cell LymphomaLeo Meriranta, Rasmus Rask Kragh Jørgensen, Annika Pasanen, et al.
Blood Advances|December 19, 2023
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trialMats Jerkeman, Arne Kolstad, Martin Hutchings, et al.
Pageof 2